Journal Article

Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients

Chen, Sheng-Qun, Zheng, Shu-Sen, Wang, Wei-Lin, Chen, Li-Ming, Zhou, Tan-Yang, Zhou, Guan-Hui, Yu, Zi-Niu, Nie, Chun-Hui, Wang, Bao-Quan, Han, Jun, Zhu, Tong-Yin, Wang, Hong-Liang, Zhang, Yue-Lin, Sun, Jun-Hui

2018

Overview

Background This study aimed to investigate the efficacy and safety of drug eluting beads transarterial chemoembolization (DEB-TACE) treatment by CalliSpheres® in Chinese patients with hepatocellular carcinoma (HCC) as well as the predicting factors for response. Methods 99 patients with HCC were consecutively enrolled in this study. All participants were treated by CalliSpheres® DEB-TACE. Clinical response was evaluated according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Common Terminology Criteria for Adverse Events (CTCAE) was used to assess the adverse events and liver dysfunction during and after the operation. Results Post treatment, 16 patients (16.2%) achieved CR and 59 (59.6%) achieved PR, the ORR was 75.8%. Subgroup analysis showed that patients with higher BCLC stage were of worse CR and ORR rates, and the CR as well as ORR between patients with cTACE history and patients without cTACE history were similar. Univariate logistic regression analysis displayed that number of nodules > 3, higher BCLC stage and previous cTACE might be correlated with worse ORR but with no statistical significance. As to liver function, CTCAE grades of laboratory indexes for liver function were increased at 1 week compared to baseline and recovered to the baseline grades at 1–3 months post operation. Besides, most of the common adverse events were light and moderate in our study. Conclusions In conclusion, DEB-TACE by CalliSpheres® was efficient and well tolerated in Chinese HCC patients, and BCLC stage, number of nodules and cTACE history were possibly correlated with treatment response.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adult / Aged / Analysis / Antibiotics, Antineoplastic - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Asian Continental Ancestry Group / Biomedical and Life Sciences / Biomedicine / Blood / CalliSpheres / cancer imaging / Cancer Research / Cancer therapies / Carcinoma, Hepatocellular - therapy / Care and treatment / Chemoembolization, Therapeutic - methods / Chemotherapy / Clinical medicine / DEB-TACE / Doxorubicin - administration & dosage / Drug delivery / Drug Delivery Systems - methods / Drug-eluting stents / Efficacy / Embolisms / Epirubicin - administration & dosage / Female / Fistula / Health Promotion and Disease Prevention / Hepatitis / Hepatocellular carcinoma / Hepatocellular carcinoma (HCC) / Humans / interventional therapeutics / Laboratories / Liver cancer / Liver diseases / Liver Neoplasms - therapy / Male / Medical imaging / Medical prognosis / Medicine/Public Health / Microspheres / Middle Aged / Mortality / Nodules / Oncology / Patients / Predictive factors / Research Article / Safety / Self efficacy / Solid tumors / Studies / Surgical Oncology / Terminology / Tumors